Full Text View
Tabular View
No Study Results Posted
Related Studies
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
This study has been completed.
Study NCT00084630   Information provided by National Cancer Institute (NCI)

First Received on June 10, 2004.   Last Updated on February 27, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Adult Fibrosarcoma
Dermatofibrosarcoma Protuberans
Recurrent Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma
Additional conditions recognized in this trial
Dermatofibrosarcoma
Fibrosarcoma
Sarcoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Connective Tissue
Neoplasms, Fibrous Tissue
Interventions listed in this trial
imatinib mesylate
laboratory biomarker analysis
Additional drug interventions recognized in this trial
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services